Scroll

nelfinavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
HIV protease inhibitors	1893	159989-64-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nelfinavir viracept nelfinavir mesylate nelfinavir mesilate	A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19. Molecular weight: 567.79 Formula: C32H45N3O4S CLOGP: 5.84 LIPINSKI: 2 HAC: 7 HDO: 4 TPSA: 101.90 ALOGS: -5.47 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nelfinavir
viracept
nelfinavir mesylate
nelfinavir mesilate

A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.

Molecular weight: 567.79
Formula: C32H45N3O4S
CLOGP: 5.84
LIPINSKI: 2
HAC: 7
HDO: 4
TPSA: 101.90
ALOGS: -5.47
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	62.90 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 14, 1997	FDA	AGOURON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	509.24	47.53	181	1617	120834	50482492
Pregnancy	209.48	47.53	66	1732	29511	50573815
Stillbirth	196.99	47.53	45	1753	5907	50597419
Viral mutation identified	170.43	47.53	32	1766	1597	50601729
Caesarean section	167.21	47.53	48	1750	15591	50587735
Abortion spontaneous	120.96	47.53	48	1750	41724	50561602
Foetal exposure during pregnancy	117.62	47.53	42	1756	27317	50576009
Premature baby	117.55	47.53	38	1760	18299	50585027
Drug resistance	108.20	47.53	36	1762	18953	50584373
Maternal drugs affecting foetus	98.64	47.53	25	1773	5052	50598274
Hypertriglyceridaemia	91.85	47.53	24	1774	5467	50597859
Blood lactic acid increased	86.66	47.53	23	1775	5562	50597764
Pathogen resistance	76.83	47.53	21	1777	5668	50597658
Live birth	69.71	47.53	25	1773	16383	50586943
Normal newborn	64.58	47.53	19	1779	6672	50596654
Multiple-drug resistance	62.78	47.53	16	1782	3298	50600028
Premature labour	62.30	47.53	21	1777	11455	50591871
Atrial septal defect	61.17	47.53	18	1780	6323	50597003
Abortion induced	58.32	47.53	19	1779	9325	50594001
Foetal death	56.65	47.53	18	1780	8162	50595164
Patent ductus arteriosus	55.78	47.53	15	1783	3805	50599521
Lipodystrophy acquired	54.54	47.53	12	1786	1317	50602009
Trisomy 21	49.58	47.53	9	1789	370	50602956

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	445.18	36.32	95	3044	2999	29568389
Mitochondrial toxicity	375.11	36.32	79	3060	2332	29569056
Exposure during pregnancy	372.67	36.32	100	3039	8454	29562934
Progressive external ophthalmoplegia	335.05	36.32	65	3074	1252	29570136
Eyelid ptosis	324.90	36.32	81	3058	5105	29566283
Foetal exposure during pregnancy	230.97	36.32	98	3041	33769	29537619
Diplopia	228.03	36.32	76	3063	13442	29557946
Premature baby	101.14	36.32	45	3094	17235	29554153
Ophthalmoplegia	98.82	36.32	25	3114	1657	29569731
Virologic failure	90.23	36.32	26	3113	2821	29568567
Viral mutation identified	89.12	36.32	25	3114	2463	29568925
Pathogen resistance	88.33	36.32	33	3106	8083	29563305
Hydrocele	76.26	36.32	21	3118	1932	29569456
Maternal drugs affecting foetus	73.99	36.32	24	3115	3869	29567519
Hypertriglyceridaemia	72.69	36.32	28	3111	7447	29563941
Caesarean section	62.89	36.32	18	3121	1905	29569483
Cryptorchism	62.71	36.32	18	3121	1924	29569464
Blood lactic acid increased	57.49	36.32	22	3117	5744	29565644
Multiple-drug resistance	54.17	36.32	19	3120	3881	29567507
Lipoatrophy	53.39	36.32	12	3127	477	29570911
Optic nerve neoplasm	53.19	36.32	8	3131	28	29571360
Neonatal disorder	52.47	36.32	13	3126	790	29570598
Pregnancy	48.93	36.32	10	3129	251	29571137
Anaemia neonatal	47.92	36.32	10	3129	279	29571109
Cardiac murmur	47.76	36.32	20	3119	6593	29564795
Hyperlactacidaemia	44.81	36.32	15	3124	2663	29568725
Drug resistance	44.54	36.32	28	3111	21512	29549876
Hypospadias	43.13	36.32	15	3124	2987	29568401
Astrocytoma, low grade	43.03	36.32	7	3132	45	29571343
Congenital anomaly	41.49	36.32	12	3127	1316	29570072

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	531.42	35.75	102	3238	3925	64491467
Mitochondrial toxicity	448.05	35.75	83	3257	2623	64492769
Progressive external ophthalmoplegia	387.97	35.75	66	3274	1261	64494131
Eyelid ptosis	328.55	35.75	80	3260	9445	64485947
Exposure during pregnancy	256.34	35.75	109	3231	77566	64417826
Viral mutation identified	250.92	35.75	53	3287	3293	64492099
Diplopia	230.55	35.75	76	3264	26689	64468703
Pregnancy	170.59	35.75	57	3283	20808	64474584
Stillbirth	169.45	35.75	39	3301	3594	64491798
Pathogen resistance	146.66	35.75	45	3295	12498	64482894
Virologic failure	144.65	35.75	34	3306	3432	64491960
Drug resistance	138.22	35.75	56	3284	35046	64460346
Multiple-drug resistance	128.05	35.75	35	3305	6467	64488925
Caesarean section	113.15	35.75	36	3304	11238	64484154
Abortion spontaneous	101.98	35.75	41	3299	25102	64470290
Ophthalmoplegia	99.70	35.75	24	3316	2678	64492714
Premature baby	75.65	35.75	20	3320	3252	64492140
Normal newborn	60.75	35.75	19	3321	5598	64489794
Optic nerve neoplasm	59.87	35.75	8	3332	24	64495368
Lipoatrophy	58.66	35.75	12	3328	633	64494759
Foetal exposure during pregnancy	56.29	35.75	17	3323	4459	64490933
Live birth	47.92	35.75	19	3321	11185	64484207
Dyslipidaemia	47.82	35.75	18	3322	9224	64486168
Maternal drugs affecting foetus	42.74	35.75	11	3329	1609	64493783
Abortion induced	42.58	35.75	15	3325	6373	64489019
Osteonecrosis	41.92	35.75	23	3317	28206	64467186
HIV-associated neurocognitive disorder	41.31	35.75	8	3332	318	64495074
Astrocytoma, low grade	40.04	35.75	6	3334	48	64495344
Blood HIV RNA increased	38.78	35.75	10	3330	1474	64493918
Hypertriglyceridaemia	37.69	35.75	16	3324	11189	64484203

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AE04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors
FDA MoA	N0000000246	HIV Protease Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35660	HIV protease inhibitors
FDA EPC	N0000175889	Protease Inhibitor
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D017320	HIV Protease Inhibitors
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D000084762	Viral Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Depressive disorder	contraindication	35489007
Diarrhea	contraindication	62315008
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Hemophilia	contraindication	90935002
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.66	acidic
pKa2	11.97	acidic
pKa3	6.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.19	DRUG MATRIX
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	5.70	DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.70	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.06	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	4.21	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	4.59	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	4.91	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.08	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	4.84	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	4.63	DRUG MATRIX
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.26	DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	4.10	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.10	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	4.68	DRUG MATRIX
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	4.65	DRUG MATRIX
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		IC50	4.74	DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.01	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.23	DRUG MATRIX
Pol polyprotein	Enzyme		Q72874_9HIV1	INHIBITOR	Ki	11	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR				WOMBAT-PK
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.62	DRUG MATRIX
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	4.86	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.24	DRUG MATRIX
Protease	Enzyme		Q9YQ12_9HIV1		Ki	10.15	CHEMBL
Protease	Unclassified		O90781_9PLVG		Ki	8.49	CHEMBL
Protease	Unclassified		Q9YQ30_9PLVG		Ki	8.68	CHEMBL

External reference:

ID	Source
4024050	VUID
N0000022055	NUI
D00899	KEGG_DRUG
159989-65-8	SECONDARY_CAS_RN
4021010	VANDF
4024050	VANDF
C0525005	UMLSCUI
CHEBI:7496	CHEBI
1UN	PDB_CHEM_ID
CHEMBL584	ChEMBL_ID
CHEMBL1205	ChEMBL_ID
D019888	MESH_DESCRIPTOR_UI
DB00220	DRUGBANK_ID
11090	IUPHAR_LIGAND_ID
7494	INN_ID
HO3OGH5D7I	UNII
64143	PUBCHEM_CID
134526	RXNORM
5162	MMSL
9815	MMSL
d04118	MMSL
006408	NDDF
006409	NDDF
108706004	SNOMEDCT_US
108707008	SNOMEDCT_US
373445001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	52959-289	TABLET, FILM COATED	250 mg	ORAL	NDA	26 sections
Viracept	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0809	TABLET, FILM COATED	625 mg	ORAL	NDA	25 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-010	TABLET, FILM COATED	250 mg	ORAL	NDA	29 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-027	TABLET, FILM COATED	625 mg	ORAL	NDA	29 sections